The study suggested that activation of the Notch1 pathway due to Notch1/FBXW7 mutations could identify patients with a favorable prognosis.168 Among 162 treated pediatric patients with T-ALL screened in the MRC UKALL2003 trial, those with double mutations of Notch1 and/or FBXW7 exhibited very positive outcomes.169 Overall, these studies indicate that Notch activation may be associated with improved early treatment response in T-ALL, and the impact on prognosis may be influenced by differences in treatment approaches. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.